Eiger Biopharmaceuticals (EIGR) Now Covered by Analysts at Ladenburg Thalmann Financial Services
Ladenburg Thalmann Financial Services started coverage on shares of Eiger Biopharmaceuticals (NASDAQ:EIGR) in a report issued on Wednesday morning. The brokerage issued a buy rating and a $32.00 target price on the biotechnology company’s stock.
Several other research analysts also recently commented on the stock. ValuEngine raised shares of Eiger Biopharmaceuticals from a sell rating to a hold rating in a research note on Sunday, December 31st. Oppenheimer set a $34.00 price target on shares of Eiger Biopharmaceuticals and gave the stock a buy rating in a research note on Thursday, December 7th. Wedbush reissued a buy rating on shares of Eiger Biopharmaceuticals in a research note on Wednesday, October 25th. Roth Capital began coverage on shares of Eiger Biopharmaceuticals in a research note on Thursday, October 19th. They set a buy rating and a $35.00 price target on the stock. Finally, Zacks Investment Research downgraded shares of Eiger Biopharmaceuticals from a buy rating to a hold rating in a research note on Tuesday, October 17th. Two analysts have rated the stock with a hold rating and seven have given a buy rating to the company. Eiger Biopharmaceuticals currently has a consensus rating of Buy and a consensus target price of $30.63.
Eiger Biopharmaceuticals (NASDAQ:EIGR) traded up $0.15 during mid-day trading on Wednesday, hitting $14.50. 126,300 shares of the company’s stock traded hands, compared to its average volume of 139,667. The stock has a market capitalization of $144.07, a P/E ratio of -2.74 and a beta of 2.54. Eiger Biopharmaceuticals has a 52-week low of $6.10 and a 52-week high of $14.84. The company has a debt-to-equity ratio of 1.19, a current ratio of 5.78 and a quick ratio of 5.78.
Eiger Biopharmaceuticals (NASDAQ:EIGR) last posted its quarterly earnings results on Thursday, November 9th. The biotechnology company reported ($1.10) EPS for the quarter, topping the consensus estimate of ($1.28) by $0.18. equities analysts forecast that Eiger Biopharmaceuticals will post -4.59 EPS for the current fiscal year.
Several hedge funds and other institutional investors have recently modified their holdings of the stock. Bank of New York Mellon Corp increased its stake in shares of Eiger Biopharmaceuticals by 6.4% in the second quarter. Bank of New York Mellon Corp now owns 14,567 shares of the biotechnology company’s stock worth $115,000 after buying an additional 871 shares during the period. JPMorgan Chase & Co. increased its stake in shares of Eiger Biopharmaceuticals by 295.8% in the third quarter. JPMorgan Chase & Co. now owns 11,705 shares of the biotechnology company’s stock worth $126,000 after buying an additional 8,748 shares during the period. Wedbush Securities Inc. purchased a new position in shares of Eiger Biopharmaceuticals in the third quarter worth $114,000. OxFORD Asset Management LLP purchased a new position in shares of Eiger Biopharmaceuticals in the third quarter worth $147,000. Finally, Susquehanna International Group LLP purchased a new position in shares of Eiger Biopharmaceuticals in the second quarter worth $114,000. 47.06% of the stock is currently owned by institutional investors.
WARNING: This story was first posted by Daily Political and is the sole property of of Daily Political. If you are viewing this story on another site, it was illegally copied and reposted in violation of U.S. and international copyright laws. The correct version of this story can be viewed at https://www.dailypolitical.com/2018/01/05/eiger-biopharmaceuticals-eigr-now-covered-by-analysts-at-ladenburg-thalmann-financial-services.html.
About Eiger Biopharmaceuticals
Eiger BioPharmaceuticals, Inc, formerly Celladon Corporation, is a clinical-stage biopharmaceutical company. The Company is focused on the development and commercialization of products for the treatment of orphan diseases. Its pipeline includes Sarasar (lonafarnib) for hepatitis delta virus (HDV), exendin (9-39) for severe hypoglycemia, and Bestatin (ubenimex) for pulmonary arterial hypertension (PAH) and lymphedema.
Receive News & Ratings for Eiger Biopharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Eiger Biopharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.